Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals, Inc. (Symbol: SLRX) is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. The company’s unique approach targets cancers with high unmet medical needs through two main types of drugs: targeted protein inhibitors and targeted protein degraders. Salarius is currently focused on two primary drug candidates: Seclidemstat (SP-2577) and SP-3164.
Seclidemstat is a small molecule inhibitor designed to modify the activity of proteins involved in gene regulation. It is currently being evaluated in a Phase 1/2 clinical trial for Ewing sarcoma, an aggressive bone and soft tissue cancer. Notably, the trial has shown promising results, with a recent partial response in an additional patient and an objective response rate of 60% among first-relapse Ewing patients treated with the combination of Seclidemstat, Topotecan, and Cyclophosphamide.
The second candidate, SP-3164, is a small molecule protein degrader aimed at targeting and destroying cancer-promoting proteins. This novel approach could offer a new avenue for cancer treatment, potentially overcoming resistance mechanisms that limit the efficacy of standard therapies.
Salarius Pharmaceuticals is committed to advancing its clinical programs and expanding its pipeline through strategic partnerships and collaborations. The company's mission is to develop transformative therapies that can significantly improve the lives of cancer patients.
Latest News:
Salarius Pharmaceuticals (NASDAQ: SLRX) announced significant preclinical findings for its novel molecular glue, SP-3164, demonstrating strong antitumor activity in models of follicular lymphoma and multiple myeloma. During the American Association for Cancer Research (AACR) Annual Meeting, two posters were presented highlighting SP-3164’s efficacy both as a single agent and in combination with established treatments such as venetoclax and bortezomib. The research showcased that SP-3164 induced apoptosis in multiple myeloma cell lines and exhibited superior activity compared to other existing therapies. This progress supports Salarius’ strategy for advancing SP-3164 in hematologic cancers as it moves closer to clinical trials planned for 2023.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced its participation in the Diamond Equity Research Emerging Growth Invitational conference on April 5, 2023. Key executives, including CFO Mark Rosenblum and Dr. Daniela Santiesteban, will present at 11:00 a.m. Eastern time, followed by a Q&A session. Salarius specializes in developing innovative cancer therapies such as seclidemstat, which is undergoing a Phase 1/2 trial for Ewing sarcoma. The company has received fast track and orphan drug designations from the FDA for this candidate. For more details, visit Salarius’ website or register for the webcast using the provided link.
Salarius Pharmaceuticals (SLRX) reported promising preclinical results for its targeted protein degrader SP-3164, showing significant anticancer activity in non-Hodgkin Lymphoma and Multiple Myeloma models. The company is on track to file an IND in the first half of 2023 and expects to initiate clinical trials later this year. Financially, Salarius reported a net loss of $31.6 million for 2022, primarily due to increased R&D expenses and a one-time goodwill impairment of $8.9 million. Cash reserves decreased to $12.1 million as of December 31, 2022, but are projected to fund operations through Q4 2023.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced the acceptance of two abstracts for presentation at the AACR Annual Meeting from April 14-19, 2023. The abstracts focus on the novel molecular glue SP-3164's activity in treating non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). One study shows SP-3164's potential as an orally available treatment for NHL, while another highlights its effectiveness in degrading cancer-promoting proteins in MM, demonstrating superior activity compared to existing therapies. Clinical trials for SP-3164 are anticipated to begin this year, emphasizing its promising role in oncology.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
What does Salarius Pharmaceuticals, Inc. specialize in?
What are the main drug candidates of Salarius Pharmaceuticals?
What is Seclidemstat (SP-2577) used for?
What is SP-3164?
What are the latest achievements of Salarius Pharmaceuticals?
Where can I find the latest news about Salarius Pharmaceuticals?
How does Salarius Pharmaceuticals aim to impact cancer treatment?
Are there any partnerships that Salarius Pharmaceuticals is involved in?
What is the focus of Salarius Pharmaceuticals' pipeline?
How can I invest in Salarius Pharmaceuticals?
